(Reuters) – Swiss food group Nestle is to buy U.S. drugmaker Pfizer’s infant nutrition business for
$11.85 billion, beating out French rival Danone in the battle for dominance of baby food in fast-growing emerging
markets.
in Orbe April 20, 2012. REUTERS/Joao Vieria
Nestle, the world’s biggest food company,
was already seen as likely to win the battle due to its deep pockets after it sold its stake in eyecare group Alcon to
Novartis, and has refrained from announcing a new share buyback program.
The fight for the Pfizer unit, which makes 85
percent of its sales in emerging markets, had intensified last week, with the price escalating sharply from bids around $10
billion after Danone was reported to have raised its offer on Friday.
The acquisition, which is subject to regulatory
approval, is expected to close in mid 2013 and will help Nestle extend its lead in the infant formula market.
“The
price tag is high, however Nestle is securing a high growth/margin business with high exposure in the emerging markets. China will become the number 3 market for
Nestle overall,” said Vontobel analyst Jean-Philippe Bertschy.
Nestle said the deal would be add to earnings per share from the first year, and would
allow cost synergies of $160 million. Bertschy estimated the deal would add about 0.5 percent to earnings per share in the
first year and 1.5 percent in the following years.
Nestle shares, which hit an all-time high of 57.50 francs ahead of
solid first-quarter results last week, fell 3.06 percent to 55.35 francs at 4 a.m. EDT as they traded ex-dividend, compared
with a 1.11 percent weaker European food and beverage index.
“Although the growth profile, attractive margins and
emerging market exposure makes this a compelling asset, we believe that the multiples being some way ahead of market
expectations may dampen near term enthusiasm for the deal,” said Citi analyst Robert Dickinson.
The $11.85 billion
value of the deal was above the $10 billion which had been expected, and ahead of previous Nestle deals in the sector when it
paid 15.7 times for Gerber and 17.6 times for Novartis Nutrition, according to Citi.
CHINESE MARKET KEY
The
Pfizer unit is a high-growth business built on its top SMA Gold brand. Some 60 percent of sales are in Asia, 30 percent in
Europe, largely Britain, and 10 percent in Latin America.
It ranks number five globally in the infant milk formula
market – the world’s fastest-growing packaged food category – after Nestle, Mead Johnson, Danone and Abbott Laboratories,
with a quarter of sale in the buoyant Chinese market.
The $6 billion Chinese market is key as it is set to double to
$12 billion by 2016 having grown at more than 20 percent a year over the last five years to feed 16 million new births a
year. Mead leads the Chinese market with a 16 percent share followed by Danone with 14 percent, Pfizer is fifth with an 8
percent share, while Nestle has just 4 percent.
Nestle’s roots go back to the 1860s development by Henri Nestle, a
pharmacist, of the first infant formula for babies whose mothers who could not breast feed.
“Pfizer Nutrition is an
excellent strategic fit and this acquisition underlines our commitment to be the world’s leading nutrition, health and
wellness company,” Chief Executive Paul Bulcke said on Monday.
The Vevey-based firm expects the acquisition will
generate sales of $2.4 billion this year and boost margins, thanks to its large exposure to fast-growing emerging
markets.
Nestle, which expects emerging markets to account for half of sales by 2020 from 41 percent last year, has
been an active player in recent emerging markets merger activity, taking stakes in two Chinese food companies.
“The
deal makes strategic sense, it really was Nestle’s deal to lose as it very much wanted to add to its Asian business and
boost growth and margins,” said Kepler analyst Jon Cox.
“The price being paid seems quite high, by my calculations
it’s at 22 times core earnings, almost as high as Danone’s infamous 2007 acquisition of Numico.”
Danone paid 12.3
billion euros in 2007 for Dutch food group Numico, at the time Europe’s largest baby food producer, paying a similar
multiple, a price many analysts said was too high.
Pfizer put its infant nutrition and animal health businesses up for
sale last July as it looks to focus on its core pharmaceuticals business.
(Additional reporting by Emma Thomasson in Zurich and
David Jones in London; Editing
by Hans-Juergen Peters)